Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Apr;63(4):1336–1339. doi: 10.1128/iai.63.4.1336-1339.1995

Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.

S J Cryz Jr 1, J U Que 1, M M Levine 1, G Wiedermann 1, H Kollaritsch 1
PMCID: PMC173155  PMID: 7890391

Abstract

The safety and immunogenicity of the live oral attenuated vaccine strains vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a were evaluated alone or in a combined bivalent formulation in four groups composed of 185 healthy European adults. All presentations were well tolerated. The serum anti-S. typhi lipopolysaccharide immunoglobulin G and immunoglobulin A antibody responses were comparable for all groups (66 to 72% seroconversion). The serum vibriocidal antibody seroconversion rate ranged from 78 to 92.5% (P > 0.05) among the groups. However, the peak and geometric mean vibriocidal antibody titers were significantly higher (P < 0.005) in the groups which received the bivalent formulation along with two doses of Ty21a than in the group which received CVD 103-HgR followed by two doses of killed Escherichia coli K-12 placebo. The ingestion of a placebo shortly after CVD 103-HgR may have suppressed the magnitude of the immune response. These findings demonstrate the feasibility of producing multivalent live oral attenuated vaccines.

Full Text

The Full Text of this article is available as a PDF (194.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett P., Clarke P., Cryz S., Jr Oral cholera vaccine well tolerated. BMJ. 1993 Nov 27;307(6916):1425–1425. doi: 10.1136/bmj.307.6916.1425-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clemens J. D., van Loon F., Sack D. A., Chakraborty J., Rao M. R., Ahmed F., Harris J. R., Khan M. R., Yunus M., Huda S. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis. 1991 Jun;163(6):1235–1242. doi: 10.1093/infdis/163.6.1235. [DOI] [PubMed] [Google Scholar]
  3. Clements M. L., Levine M. M., Young C. R., Black R. E., Lim Y. L., Robins-Browne R. M., Craig J. P. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982 Apr;145(4):465–473. doi: 10.1093/infdis/145.4.465. [DOI] [PubMed] [Google Scholar]
  4. Cryz S. J., Jr, Levine M. M., Kaper J. B., Fürer E., Althaus B. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine. 1990 Dec;8(6):577–580. doi: 10.1016/0264-410x(90)90012-b. [DOI] [PubMed] [Google Scholar]
  5. Cryz S. J., Jr, Levine M. M., Losonsky G., Kaper J. B., Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect Immun. 1992 Sep;60(9):3916–3917. doi: 10.1128/iai.60.9.3916-3917.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cryz S. J., Jr Post-marketing experience with live oral Ty21a vaccine. Lancet. 1993 Jan 2;341(8836):49–50. doi: 10.1016/0140-6736(93)92522-u. [DOI] [PubMed] [Google Scholar]
  7. Cryz S. J., Jr, Vanprapar N., Thisyakorn U., Olanratmanee T., Losonsky G., Levine M. M., Chearskul S. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun. 1993 Mar;61(3):1149–1151. doi: 10.1128/iai.61.3.1149-1151.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Glass R. I., Svennerholm A. M., Khan M. R., Huda S., Huq M. I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985 Feb;151(2):236–242. doi: 10.1093/infdis/151.2.236. [DOI] [PubMed] [Google Scholar]
  9. Kotloff K. L., Wasserman S. S., O'Donnell S., Losonsky G. A., Cryz S. J., Levine M. M. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun. 1992 Oct;60(10):4430–4432. doi: 10.1128/iai.60.10.4430-4432.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Levine M. M., Ferreccio C., Black R. E., Tacket C. O., Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis. 1989 May-Jun;11 (Suppl 3):S552–S567. doi: 10.1093/clinids/11.supplement_3.s552. [DOI] [PubMed] [Google Scholar]
  11. Levine M. M., Ferreccio C., Cryz S., Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 1990 Oct 13;336(8720):891–894. doi: 10.1016/0140-6736(90)92266-k. [DOI] [PubMed] [Google Scholar]
  12. Levine M. M., Herrington D., Murphy J. R., Morris J. G., Losonsky G., Tall B., Lindberg A. A., Svenson S., Baqar S., Edwards M. F. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest. 1987 Mar;79(3):888–902. doi: 10.1172/JCI112899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Levine M. M., Kaper J. B., Herrington D., Ketley J., Losonsky G., Tacket C. O., Tall B., Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–470. doi: 10.1016/s0140-6736(88)90120-1. [DOI] [PubMed] [Google Scholar]
  14. Levine M. M., Kaper J. B. Live oral vaccines against cholera: an update. Vaccine. 1993;11(2):207–212. doi: 10.1016/0264-410x(93)90019-t. [DOI] [PubMed] [Google Scholar]
  15. Levine M. M., Taylor D. N., Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J. 1989 Jun;8(6):374–381. doi: 10.1097/00006454-198906000-00010. [DOI] [PubMed] [Google Scholar]
  16. Olanratmanee T., Levine M., Losonsky G., Thisyakorn V., Cryz S. J., Jr Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children. J Infect Dis. 1992 Aug;166(2):451–452. doi: 10.1093/infdis/166.2.451. [DOI] [PubMed] [Google Scholar]
  17. Reisinger E. C., Grasmug E., Krejs G. J. Antibody response after vaccination against typhoid fever in Kurdish refugee camp. Lancet. 1994 Apr 9;343(8902):918–919. doi: 10.1016/s0140-6736(94)90038-8. [DOI] [PubMed] [Google Scholar]
  18. Simanjuntak C. H., O'Hanley P., Punjabi N. H., Noriega F., Pazzaglia G., Dykstra P., Kay B., Suharyono, Budiarso A., Rifai A. R. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis. 1993 Nov;168(5):1169–1176. doi: 10.1093/infdis/168.5.1169. [DOI] [PubMed] [Google Scholar]
  19. Simanjuntak C. H., Paleologo F. P., Punjabi N. H., Darmowigoto R., Soeprawoto, Totosudirjo H., Haryanto P., Suprijanto E., Witham N. D., Hoffman S. L. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet. 1991 Oct 26;338(8774):1055–1059. doi: 10.1016/0140-6736(91)91910-m. [DOI] [PubMed] [Google Scholar]
  20. Tacket C. O., Losonsky G., Nataro J. P., Cryz S. J., Edelman R., Kaper J. B., Levine M. M. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis. 1992 Oct;166(4):837–841. doi: 10.1093/infdis/166.4.837. [DOI] [PubMed] [Google Scholar]
  21. Taylor D. N., Pollard R. A., Blake P. A. Typhoid in the United States and the risk to the international traveler. J Infect Dis. 1983 Sep;148(3):599–602. doi: 10.1093/infdis/148.3.599. [DOI] [PubMed] [Google Scholar]
  22. Threlfall E. J., Said B., Rowe B. Emergence of multiple drug resistance in Vibrio cholerae O1 El Tor from Ecuador. Lancet. 1993 Nov 6;342(8880):1173–1173. doi: 10.1016/0140-6736(93)92156-n. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES